The Earliest Carefully Controlled Clinical Trial Evaluating Oral Pharmacotherapy (Yohimbine) in ED.- A Description of the Pioneering Work That Led to the First Approved Agents for ED: Giles Brindley, the Needle, and the Penis (Phenoxybenzamine).- The Pivotal Study Showing That Intracorporal Injection of Vasoactive Agents (Papaverine or Phenoxybenzamine) Was Effective Pharmacotherapy.- The First Placebo-Controlled Study on the Benefits of Intracorporal Administration of Vasorelaxant Agents to ED Patients (Papaverine/Phentolamine Combination).- Representative Study on the Use of Yohimbine in the Treatment of Organic ED.- Defining the Therapeutic Ratio for Intracavernosal Administration of Prostaglandin E1 (Alprostadil).- An Elegant Long-Term Trial Assessing the Clinical Profile of Intracavernosal Prostaglandin E1 (Alprostadil).- Evaluation of Novel Combination (Vasoactive Intestinal Polypeptide and Phentolamine) as Intracavernosal Therapy.- Now-Classic Study on the Use of Intraurethral Prostaglandin E1 (Alprostadil).- Route of Administration Has a Considerable Impact on Clinical Profile: A Comparison of Intraurethral and Intracavernosal Alprostadil.- First Clinical Data on Sildenafil: The Arrival of Oral Pharmacotherapy.- Original "Gold Standard" Clinical Trial of Sildenafil in ED.- Pilot Study Showing Benefit of Clinical Response to Apomorphine Sublingual (SL).- A Viable Alternative to PDE Inhibitors: Definition of Therapeutic Ratio of Apomorphine Sublingual (SL) in Patients with ED.- Summary of Clinical Trials of Phentolamine.- Impact of Testosterone Replacement in Androgen-Deficient Males.- Evaluation of Psychotherapy for Patients and Partners.- Quantification of Benefit of a Vacuum Device on Erectile Function.- Pioneering Clinical Trial of Surgical Procedures.
